In contrast, the cell lines we employed were HBV-, and our previous studies report that increased FABP4 expression was only detected in patients with ALD or NAFLD, and not those with an underlying HBV/HCV infection. Here, FABP4 is linked to metabolic dysfunction-associated steatotic liver disease.